We agree with the reviewer that it would be interesting to see how NR2F1 levels would change with endocrine therapy. However, we do not have access to cohorts that include tumor samples before and after neoadjuvant endocrine therapy at this point. What we do have access to regarding endocrine therapy is a cohort comparing responders and non- responders to neoadjuvant endocrine therapy (GSE145325). We found that NR2F1 expression between responders and non-responders to endocrine therapy was not different. We added this to the results section as follows.
Previous studies mentioned that NR2F1 was highly expressed in DTCs [67].